trial · primary record
Gene-modified (GM) T cell therapy
Neoplasms
| Phase | Phase 2, Phase 3 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 1541 |
| Primary completion | 2043-05-29 |
| Primary endpoint | Incidence of delayed Adverse Events (AEs) |
| Registry ID | NCT03435796 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-11-02T15:42:39.683Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT03435796
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.